Close Menu

NEW YORK – Fulgent Genetics intends to sell $22.5 million in shares of its common stock, the firm said in a regulatory document on Friday.

Separately, the company said it entered an agreement with investment bank Piper Jaffray to sell $30 million of its shares from time to time. The $22.5 million offering disclosed in a prospectus filed last week with the US Securities and Exchange Commission is part of that deal. It said that proceeds will go toward working capital and general corporate purposes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more. 

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

Feb
20
Sponsored by
Thermo Fisher Scientific

This webinar will discuss the use of 3’ mRNA sequencing to reduce the cost of gene expression studies on Illumina NGS systems.

Feb
25
Sponsored by
Loop Genomics

This webinar will discuss a study that used long-read transcriptome sequencing to explore the distribution of isoforms in colon cancer samples and their metastasis counterparts.